<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT942-8923</title>
	</head>
	<body>
		<main>
			<p>940518 FT  18 MAY 94 / UK Company News: Celltech near to asthma drug deal Celltech, the biotechnology company which floated on the stock market in December 1993, will within months sign a collaborative deal on the development of an asthma drug worth at least Pounds 20m. Mr Peter Fellner, chief executive, said yesterday he was in advanced talks with four companies interested in taking the asthma treatment through the later, more expensive, clinical trials and to market. The deal would involve royalty payments to Celltech and 'other mechanisms' for sharing profits, he said. News of the deal came as the company released its interim results for the six months to the end of March 1994. The proceeds from the flotation lifted the company's net cash position - one of the most important figures in a biotechnology company's balance sheet - to Pounds 40.3m (Pounds 11.4m). Turnover rose from Pounds 5.5m to Pounds 6.5m as the biologics division boosted sales of materials to pharmaceutical companies. This figure is likely to be much lower in the second half as production stops for new and larger equipment to be installed. Sales of biologics, and a Pounds 1.5m progress payment from Bayer, helped limit the half-year pre-tax loss to a little changed Pounds 4.4m (Pounds 4.3m).</p>
		</main>
</body></html>
            